Content
04/01/2025
Cambridge, MA USA
AIRNA
completed $155 million Series B Round funding. Investors include
Venrock, Forbion Capital Partners, RTW Investments, Nextech Invest, ARCH Venture Partners, +ND Capital.
About
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
